Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia

BACKGROUND: The time‐limited combination of venetoclax and obinutuzumab (VenG) was established by the German CLL Study Group in the CLL14 trial for the upfront management of newly diagnosed chronic lymphocytic leukemia (CLL), showing a superior progression free survival benefit. The incidence of gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuels, Courtney, Abbott, Diana, Niemiec, Sierra, Tobin, Jennifer, Falco, Angela, Halsema, Keri, Kamdar, Manali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124494/
https://www.ncbi.nlm.nih.gov/pubmed/34250757
http://dx.doi.org/10.1002/cnr2.1505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124494/
https://www.ncbi.nlm.nih.gov/pubmed/34250757
http://dx.doi.org/10.1002/cnr2.1505

Ejemplares similares